US surveillance data show a dramatic rise in the incidence of a particularly worrisome form of multidrug-resistant bacteria in hospital patients, researchers from the Centers for Disease Control and Prevention (CDC) reported yesterday in Emerging Infectious Diseases.
The data are from the CDC’s Emerging Infections Program (EIP) Multi-site Gram-negative Surveillance Initiative, which collects and analyzes bacterial isolates from 10 locations around the country to monitor the incidence of carbapenem-resistant Enterobacterales (CRE). Infections caused by CRE—which includes carbapenem-resistant strains of Escherichia coli, Klebsiella pneumoniae, and Enterobacter—are among the superbugs the CDC keeps track of because they are resistant to multiple classes of antibiotics and are a major concern for hospital patients.
In 2022, an estimated 13,387 CRE infections occurred in US hospital patients.
The isolates were all tested for the presence of carbapenemase genes, which confer broad resistance to beta-lactam antibiotics and can be shared among bacterial species. Of the 1,288 carbapenemase-producing CRE identified from 2016 to 2023, blaKPC was the most common carbapenemase gene detected (79%), followed by blaNDM (20.6%), blaOXA-48-like (7.5%), blaIMP (0.6%), and blaVIM (0.5%).
But the proportion of isolates carrying blaNDM, which was once rare in the United States, rose from 5.4% in 2016 to 39.8% in 2023. The increase was seen most prominently in E coli, with blaNDM representing 73% of all carbapenemase-producing E coli in 2023.
“The increase of blaNDM is alarming given that NDM-producing CRE are more resistant than other CRE isolates,” the study authors wrote, adding that they are resistant to some of the newer beta-lactam combination antibiotics that have been developed specifically for CRE infections, which further limits treatment options.
Clinicians should be on the lookout
The researchers say further investigation is needed to see if the increase is occurring nationwide, to compare the characteristics of patients infected with NDM-producing CRE versus those with blaKPC, and to determine whether the increase is related to clonal expansion.
“Our findings should alert clinicians to the increase in blaNDM and encourage mechanism testing in clinical laboratories,” they wrote.